← Leaderboards
Pablo Tebas
University Of Pennsylvania
$38,856,630
Attributed
$53,330,421
Total exposure
16
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.7M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$53,330,421 · 16
By mechanism
UM1$28,947,582 · 1
P30$12,213,439 · 4
U01$6,854,712 · 1
U19$3,327,293 · 2
P01$1,373,542 · 1
R21$348,407 · 1
Top collaborators
- Ian Frank13 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Ian Frank$25,757,892
- Michael Holmes$2,416,645
- Carl H. June$35,377,952
- James L Riley$56,591,102
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Judith S. Currier · University Of California Los Angeles$284,675,012
Research focus
Research PersonnelHiv InfectionsFacultyPathogenesisPreventionMentorsLeadershipClinical ResearchProgramsStructureResourcesTrainingNext GenerationAcquired Immunodeficiency SyndromeWorking GroupInnovationCommunitiesCollaborationsPhiladelphiaUnited States National Institutes Of HealthFundingClinical TrialsAids Clinical Trial GroupClinical Trials Unit
Grant awards (56)
University of Pennsylvania HIV Clinical Trials Unit$2,761,412
UM1 · FY2025 · AI
University of Pennsylvania HIV Clinical Trials Unit$2,946,326
UM1 · FY2024 · AI
University of Pennsylvania HIV Clinical Trials Unit$3,487,235
UM1 · FY2023 · AI
Developmental Core$815,816
P30 · FY2023 · AI · contact PI
University of Pennsylvania HIV Clinical Trials Unit$3,313,023
UM1 · FY2022 · AI
Developmental Core$2,357,051
P30 · FY2022 · AI · contact PI
University of Pennsylvania HIV Clinical Trials Unit$3,690,931
UM1 · FY2021 · AI
Developmental Core$1,310,467
P30 · FY2021 · AI · contact PI
Philadelphia HIV Therapeutics and Prevention Clinical Trials Unit$2,464,363
UM1 · FY2020 · AI · contact PI
Developmental Core$479,295
P30 · FY2020 · AI · contact PI
Philadelphia HIV Therapeutics and Prevention Clinical Trials Unit$299,668
UM1 · FY2020 · AI · contact PI
Philadelphia HIV Therapeutics and Prevention Clinical Trials Unit$2,942,898
UM1 · FY2019 · AI · contact PI
Developmental Core$1,094,331
P30 · FY2019 · AI · contact PI
A PHASE I STUDY OF C34-CXCR4 MODIFIED CD4 T CELLS IN HIV-1 INFECTED INDIVIDUALS$556,468
U19 · FY2019 · AI · contact PI
Philadelphia HIV Therapeutics and Prevention Clinical Trials Unit$1,215,815
UM1 · FY2018 · AI · contact PI
A PHASE I STUDY OF C34-CXCR4 MODIFIED CD4 T CELLS IN HIV-1 INFECTED INDIVIDUALS$920,639
U19 · FY2018 · AI · contact PI
Development Core$457,923
P30 · FY2018 · AI · contact PI
Philadelphia HIV Therapeutics and Prevention Clinical Trials Unit$1,215,815
UM1 · FY2017 · AI · contact PI
Development Core$715,719
P30 · FY2017 · AI · contact PI
A PHASE I STUDY OF C34-CXCR4 MODIFIED CD4 T CELLS IN HIV-1 INFECTED INDIVIDUALS$678,794
U19 · FY2017 · AI · contact PI
Development Core$1,231,073
P30 · FY2016 · AI · contact PI
Philadelphia HIV Therapeutics and Prevention Clinical Trials Unit$1,230,515
UM1 · FY2016 · AI · contact PI
A PHASE I STUDY OF C34-CXCR4 MODIFIED CD4 T CELLS IN HIV-1 INFECTED INDIVIDUALS$595,143
U19 · FY2016 · AI · contact PI
Philadelphia HIV Therapeutics and Prevention Clinical Trials Unit$1,315,740
UM1 · FY2015 · AI · contact PI
A PHASE I STUDY OF C34-CXCR4 MODIFIED CD4 T CELLS IN HIV-1 INFECTED INDIVIDUALS$576,249
U19 · FY2015 · AI · contact PI
Development Core$469,034
P30 · FY2015 · AI · contact PI
Philadelphia HIV Therapeutics and Prevention Clinical Trials Unit$2,063,841
UM1 · FY2014 · AI · contact PI
Development Core$643,455
P30 · FY2014 · AI · contact PI
Developmental$322,959
P30 · FY2013 · AI · contact PI
Developmental$892,822
P30 · FY2012 · AI · contact PI
Developmental$379,364
P30 · FY2011 · AI · contact PI
Developmental$374,241
P30 · FY2010 · AI · contact PI
Developmental$332,448
P30 · FY2009 · AI · contact PI
SWITCHING TO A PROTEASE INHIBITOR-CONTAINING, NUCLEOSIDE-SPARING REGIMEN$5,120
P41 · FY2009 · RR · contact PI
Core--Developmental Facility$337,441
P30 · FY2008 · AI · contact PI
Human Studies of NK-1R anatogonists in HIV-1 (project 4)$325,641
P01 · FY2008 · MH · contact PI
AIDS CLINICAL TRIALS UNIT$725,484
U01 · FY2007 · AI · contact PI
Human Studies of NK-1R anatogonists in HIV-1 (project 4)$432,368
P01 · FY2007 · MH · contact PI
AIDS CLINICAL TRIALS UNIT$1,457,025
U01 · FY2006 · AI · contact PI
Human Studies of NK-1R anatogonists in HIV-1 (project 4)$403,991
P01 · FY2006 · MH · contact PI
Mitochondria And Metabolic Complications Of HIV$164,907
R21 · FY2006 · AI · contact PI
SWITCHING PROTEASE INHIBITOR COMBO ANTIRETROVIRAL THERAPY TO NEVIRAPINE FOR HIV$13,924
P41 · FY2006 · RR · contact PI
AIDS CLINICAL TRIALS UNIT$1,576,620
U01 · FY2005 · AI
Human Studies of NK-1R anatogonists in HIV-1 (project 4)$211,542
P01 · FY2005 · MH
Mitochondria And Metabolic Complications Of HIV$183,500
R21 · FY2005 · AI
AIDS CLINICAL TRIALS UNIT$1,448,316
U01 · FY2004 · AI
SWITCHING PROTEASE INHIBITOR COMBO ANTIRETROVIRAL THERAPY TO NEVIRAPINE FOR HIV$15,987
P41 · FY2004 · RR
AIDS CLINICAL TRIALS UNIT$1,647,267
U01 · FY2003 · AI
ACTG 384--Protease and/or nonnucleoside reverse transcriptase inhibitors in HIV$0
M01 · FY2002 · RR
ACTG 328--PHASE II STUDY RECOM. HUMAN IL-2 IN HIV HAART$0
M01 · FY2002 · RR
STRATEGIC MANAGEMENT OF ANTIRETROVIRALS IN HIV INFECTION$116,452
K23 · FY2001 · AI
ACTG 384--Protease and/or nonnucleoside reverse transcriptase inhibitors in HIV$0
M01 · FY2001 · RR
ACTG 328--PHASE II STUDY RECOM. HUMAN IL-2 IN HIV HAART$0
M01 · FY2001 · RR
STRATEGIC MANAGEMENT OF ANTIRETROVIRALS IN HIV INFECTION$113,963
K23 · FY2000 · AI
ACTG 384--Protease and/or nonnucleoside reverse transcriptase inhibitors in HIV$0
M01 · FY2000 · RR
ACTG 328--PHASE II STUDY RECOM. HUMAN IL-2 IN HIV HAART$0
M01 · FY2000 · RR